![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/nodtheras-nlrp3-inhibitor-shows-further-obesity-promise-phase-1b2a-trial
https://endpts.com/nodthera-touts-potential-weight-loss-effect-of-nlrp3-inhibitors/
https://www.prnewswire.com/news-releases/nodthera-announces-positive-phase-1-study-readouts-for-the-nlrp3-inflammasome-inhibitors-nt-0796-and-nt-0249-301629146.html
https://www.prnewswire.com/news-releases/nodthera-announces-progress-of-nt-0796-a-novel-nlrp3-inflammasome-inhibitor-into-a-phase-1-first-in-human-study-301415820.html
https://seekingalpha.com/news/3616633-roche-doubles-down-on-promising-inflammation-field-inflazome-buy